|
11th International AIDS ConferenceVancouver, British Columbia — July 7-12, 1996 |
Table of Contents - MondayMo = Monday, Tu = Tuesday, We = Wednesday, Th = Thursday, Lb = Late-Breaker Cite as: Int Conf AIDS. 1996 Jul 7-12;11:Abstract No. xx |
| PLENARY Abstracts - Monday, July 8 Mo.01 thru Mo.05 |
|
| Mo.01* | Advances in Antiretroviral Therapy and Viral Load Monitoring Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.01) Hammer, Scott; Division of Infectious Diseases, Deaconess Hospital and Harvard Medical School, Boston, MA USA Recent developments in the field of antiretroviral therapy have led to substantial advances in the approach to management of HIV infected persons. |
| Mo.02 | HIV genetic diversity. Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.02) McCutchan FE, Salminen MO, Carr JK, Burke DS; Henry M. Jackson Foundation, Rockville, MD, USA. Fax: 301-762-7460. E-mail: fmccutchan@hiv.hjf.org. Introduction: HIV-1 evolves by the rapid accumulation of mutations and by recombination; both processes are actively contributing to its genetic diversity. Many new full-length sequences of HIV-1 isolates have been obtained, permitting, for the first time, a complete evaluation both of the genetic relationships among s |
| Mo.03 | The epidemic of HIV among young gay men. Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.03) de Wit J; Dept. of Social and Organizational Psychology, University of Utrecht, Utrecht, The Netherlands. Fax: 31-30-253-7584. E-mail: wit@fsw.ruu.nl. Summary: The AIDS crisis is not over was the title of a manifestation in the Museum of Modern Art in Amsterdam in the early 1990s. Given that this outcry is still valid to date, it is also the leading thought of this presentation on the HIV epidemic among young gay men. It will be argued that in industrialised nations, |
| Mo.04 | Narcotic drug abuse, the Swedish experience. Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.04) Grunewald A; Akersberga, Sweden. Fax: 46-8540-60669. The restrictive Swedish drug policy is considered to be successful in keeping narcotic drug abuse on a relatively low level and has therefore attracted international attention. The Swedish laws are well adjusted to the three UN Conventions on Narcotic Drugs (1961, 1971, 1988). The combination of resources for preventiv |
| Mo.05 | The failure of prohibition as a drug control strategy: the case of AIDS. Int Conf AIDS 1996 Jul 7-12; 11:2 (abstract no. Mo.05) Drucker E; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA. Fax: 718-798-6378. E-mail: drucker@aecom.yu.edu. Illicit drug use and addiction are now the single most dynamic feature of the global AIDS epidemic, capable of igniting explosive regional spread of HIV infection: In southeast Asia, over 1 million new HIV infections have occurred in the past decade. The failure to effectively regulate addictive drugs through prohibiti |
| ORAL Abstracts - Monday, July 8 Mo.A.100 thru Mo.D.603 |
|
| Mo.A.100 | Chemically inactivated whole HIV vaccine induces cellular responses in mice. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.100) Addawe MD, Fabrizzi F, Dourmashkin R, Wilson S, Oxford JS; Department of Academic Virology and Retroscreen Ltd., London Hospital Medical College, London, UK. Objectives: To investigate the immune response in mice to an experimental whole virus chemically inactivated HIV-1 vaccine. Methods and Results: Groups of female mice (Balb/c) were immunised with two doses (10 micrograms and 1 microgram) of a whole HIV MN virus grown in C8166 cells. The vaccine production procedure inv |
| Mo.A.101 | Efficacy evaluation of conventional dual-subtype HIV vaccine. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.101) Yamamoto JK, Mison M, Elyar J, Tellier MC, Pu R; Univ. of Florida, Dept. of Pathobiology, College of Vet. Med., Gainesville, FL. Fax: 904-392-7128. Objective: To evaluate the immunogenicity and prophylactic efficacy of dual-subtype infected cell vaccine against homologous and heterologous FIV subtype challenges in domestic cats. Methods: Dual-subtype FIV vaccine was developed from two singly-infected (subtype A or D) cell lines that were inactivated and mixed with |
| Mo.A.102 | Adenovirus host range mutant-SIV recombinant vaccine trial in rhesus macaques. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.102) Buge SL, Lubeck M, Kalyan N, Cheng S, Richardson E, Markham P, Miller C, Udem S, Robert-Guroff M; NIH, Bethesda, MD. Fax: 301-496-8394. Objective: To evaluate a prime-boost vaccine regimen using an adenovirus host range mutant (Ad5hr)-SIVsm envelope recombinant and native SIV251 gp120 for protective efficacy against vaginal transmission of SIV. Methods: Six adult female macaques were immunized orally and intranasally at 0 weeks and intratracheally at 1 |
| Mo.A.103 | Immunization with SIVmne envelope (gp160) vaccines protected macaques against intrarectal challenge by uncloned virus. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.103) Polacino P, Stallard V, Klaniecki J, Brown C, Watanabe R, Morton WR, Benveniste RE, Hu SL; University of Washington, Seattle, WA, USA. Objective: Envelope (gp160)-based vaccines, when used in a live virus priming and subunit protein boosting regimen, protected macaques from intravenous and intrarectal challenge by a cloned homologous virus SIVmne E11S. In the present study, we investigated the breadth of the protective immunity elicited by the envelop |
| Mo.A.104 | Immune responses in cynomolgus macaques infected with pathogenic or attenuated SIV. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.104) Rud EW, Sheering A, Bogdanovic D, Ko D, Vogel T, Cook N, Hall G, Cranage MP, Parenteau M, Beausoleil N, Fournier J; Health Canada, LCDC, National Laboratory for HIV Pathogenesis, Ottawa, Ontario, Canada. Fax: 613-957-7238. E-mail: erud@hpb.hwc.ca. Objective: To determine the immune responses induced by infection of macaques with either an attenuated or pathogenic variant of SIVmac32H and ultimately to correlate these to the protection induced against subsequent heterologous challenge with virus derived from SIVsmm. Methods: Three groups of 8 cynomolgus macaques |
| Mo.A.103 | Immunization with SIVmne envelope (gp160) vaccines protected macaques against intrarectal challenge by uncloned virus. Int Conf AIDS 1996 Jul 7-12; 11:4 (abstract no. Mo.A.103) Polacino P, Stallard V, Klaniecki J, Brown C, Watanabe R, Morton WR, Benveniste RE, Hu SL; University of Washington, Seattle, WA, USA. Objective: Envelope (gp160)-based vaccines, when used in a live virus priming and subunit protein boosting regimen, protected macaques from intravenous and intrarectal challenge by a cloned homologous virus SIVmne E11S. In the present study, we investigated the breadth of the protective immunity elicited by the envelop |
| Mo.A.140 | The peripheral deletion of Vgamma9/Vdelta2 in HIV-infected donors is associated with a proliferative anergy to non-peptidic ligand TUBAg and a defect in cytokine secretion. Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. Mo.A.140) Boullier S, Poccia F, Lecoeur H, Fournieo JJ, Gougeon ML; Unite D'oncologie Virale, Institut Pasteur, Paris, France. Objectives: Since we have previously reported a strong peripheral decrease of peripheral Vdelta2 gammaT lymphocytes in asymptomatic HIV-infected donors, the objective of this study was to characterize whether this decrease was associated with an alteration of the repertoire and the functions of these gamma cells. |
| Mo.A.141 | IL-15 supports anti-HIV-1 cytotoxic T cell and NK activity with less induction of HIV-1 replication than IL-2. Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. Mo.A.141) Skolnik PR, Wang A, Fabry J, Lieberman J; New England Medical Center, Boston, MA. Fax: 617-636-3216. E-mail: paul.skolnik@es.nemc.org. Objective: To determine the effects of interleukin-15 (IL-15) on HIV-1 replication and specific anti-HIV cytotoxic T cell (CTL) activity in comparison with IL-2 , which shares beta and gamma receptor chains with IL-15. Methods: IL-15- or IL-2-prestimulated PBMC from HIV-seronegative donors (N=6) were infected with HIV- |
| Mo.A.142 | Characterization of antibody, cytokine and complement levels in cervicovaginal (CVL) fluid in HIV-infected and uninfected women. Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. Mo.A.142) D'Amico RD, Sha BE, Landay AL, Spear GT, Massad LS, Padnick J, Payne G, Charles LA, Benson CA; Section of Infectious Disease, Rush Medical College, Chicago IL. Objective: To characterize antibody, cytokine, and complement levels in CVL fluid and to determine associations with HIV status, concurrent genital infection, and/or cervical dysplasia or HPV . Methods: Twenty-one women participating in the Women s Interagency HIV Study underwent CVL collection using 10 cc of sterile N |
| Mo.A.143 | Mechanisms of down-modulation and release of TNF receptor induced by HIV-1 on cultured human monocytes. Int Conf AIDS 1996 Jul 7-12; 11:5 (abstract no. Mo.A.143) Rimaniol AC, Boussin FD, Dormont D, Bach JF, Zavala F; Hopital Necker, Paris, France. Fax: 33-1-43-06-23-88. Objective: To investigate the cellular mechanisms involved in the profound remodeling of the TNF receptor expression induced by HIV-1 LAI infection of human blood monocytes. Methods: Adherent monocytes isolated from blood of HIV-1 seronegative donors were cultured for various periods in RPMI 1640 medium supplemented wi |
| Mo.A.144 | 2-5A synthetase: activation by HIV-1 TAR RNA and RRE RNA and modulation by propentofylline in HIV-1 infected CEM cells. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.144) Leuck J, Scheffer U, Muller WE, Schroder HC; Inst. of Physiological Chemistry, University, Mainz, Germany. Fax: 49-6131-395243. E-mail: leuck@mzdmza.zdv.uni-mainz.de. Objective: To determine the structural elements of HIV-1 RNAs (TAR RNA and RRE RNA) that are able to activate the antiviral 2 ,5 -oligoadenylate (2-5A) system and to search for compounds that prevent the decrease in interferon (IFN)-inducible 2-5A synthetase activity during later stages of infection. Methods: Human T l |
| Mo.A.145 | Secretion of multiple chemokines in U1 cells: auto-crine upregulation of viral expression by MCP-1. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.145) Biswas P, Delfanti F, Vicenzi E, Sozzani S, Moro M, Mantovani A, Poli G; San Raffaele Scienific Institute, Milan, Italy. Fax: 39-2-2643-7989. Objective: To investigate the role of chemokines on HIV expression in the latently infected promonocytic UI cell line that is characterized by virus inducibility by several cytokines. Methods: HIV expression was measured in culture supernatants by the reverse transcriptase (RT) activity assay. Chemokine secretion: RANT |
| Mo.A.150 | Efficacy of a DNA vaccination to induce neutralizing antibody and cytotoxic cells against HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.150) Fukushima J, Hamajima K, Asakura Y, Bukawa H, Tsuji T, Xin KQ, Nishioka K, Cullen BR, Okuda K; Yokohama City University School of Medicine, Yokohama, Japan. Fax: 81-45-787-2509. E-mail: jfukusim@med.yokohama-cu.ac.jp. Objective: The efficacy of DNA vaccines for protecting HIV-1 infection was studied by using expression plasmids for Gag, Env, and Rev proteins. Methods: We constructed expression vectors for HIV-1 genes driving cytomegalovirus promoter. These expression plasmids were injected with cationic liposomes into mice, rabbits, |
| Mo.A.151 | The combination of DNA and peptide vaccines induces strong immunities against HIV-1 in both humoral and CMI. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.151) Hamajima K, Fukushima J, Kaneko T, Bukawa H, Tsuji T, Xin KQ, Asakura Y, Okuda K, Nishioka K, Okuda K; Yokohama City University, Yokohama, Japan. Fax: 81-45-787-2509. Objective: We have reported that the synthetic peptide vaccine (VC1) against HIV induced a high level of neutralizing antibodies for various HIV isolates, and the DNA vaccine against HIV induced prolonged high CTI level. In the present study, we examined whether the combination of DNA vaccine and the peptide vaccine co |
| Mo.A.152 | A macromolecular multicomponent peptide vaccine candidate induces mucosal immunity against HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.152) Hiroki B, Asakura Y, Tsuji T, Xin KQ, Sasaki S, Hamajima K, Fukushima J, Kawamoto S, Fujita K, Okuda K; Yokohama City University School of Medicine, Yokohama, Japan. Fax: 81-45-785-8438. Objective: To induce HIV-1-specific mucosal IgA antibody with neutralizing activity is of importance for development of HIV vaccine. Induction of secretory IgA antibody against HIV-1 was studied by oral, rectal and vaginal immunization with a new synthetic peptide vaccine candidate (VC1). Method: VC1 was composed of pe |
| Mo.A.153 | High dose HIV-1 MN recombinant gp160 (rgp160) vaccine induces anti-v3 MN, and IgG1-4 and IgA anti-rgp160 antibodies. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.153) Gorse GJ, McElrath MJ, Belshe RB, Corey L, Matthews T, Eibl M, Kennedy D, Frey S, Hsieh R, Walker MC; Division of Infectious Diseases, Saint Louis Univ. Health Sciences Center, St. Louis, MO. Fax: 314-771-3816. E-mail: gorsemd@sluvca.slu.edu. Objective: To evaluate the safety and immunogenicity of a mammalian cell-produced HIV-1 MN rgp160 vaccine (IMMUNO-AG) at a high dose in low-risk, HIV-1 uninfected volunteers. Methods: In an ongoing, double-blind, randomized study, subjects received 800 micrograms MN rgp160 at 0,1, and 6 months (N=8) or at 0,2, and 8 mo |
| Mo.A.154 | Chimeric human immunodeficiency virus gag particles as an antigen presenting vehicle. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.154) Nariyoshi H, Yasuda A, Kurata T, Kojima A; Dept. of Pathology, NIH, Tokyo, Japan. Fax: 3-5285-1189. E-mail: nhoshika@nih.go.jp. Objective: Viral antigens usually show the highest immunogenicity when they form virus-like particle structures. In this study, we examined whether human immunodeficiency virus (HIV) Gag particles work as immunogenic carriers for a hepatitis C virus (HCV) core epitope. Methods: The HIV-1 gag gene (BH10) was deleted of |
| Mo.A.155 | Immunogenicity of a live recombinant canarypox virus expressing gp120tm-MN/gag/protease-LAI (vCP205) boosted with a p24e/v3-MN peptide (CLTB-36) in HIV-negative volunteers (anrs vac 03). Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.155) Salmon D, Excler JL, Finkielsztejn L, Chapuis L, Heshmati F, Gluckman JC, Autran B, Meignier B, Klein M, Sicard D; Hopital Cochin, Medecine Interne, Paris, France. Fax: 33-1-43 26 88 92. E-mail: Laufink@pratique.fr. 30 healthy volunteers at low risk for HIV infection were immunized with vCP205 at 105.8 TCID50 and or CLTB-36 240 micrograms, and randomly assigned. Results: At month 7 of lymphoproliferative response (LPR) and cytotoxic T lymphocyte activity (CTL) were as follows: (table: see text) Neutralizing antibodies to HIV-1 MN |
| Mo.A.156 | HIV-1 Pr55gag virus-like particles allow the access of polyproteins and defined epitopes to the MHC-I presentation-pathway. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.156) Ludwig D, Schirmbeck R, Reimann J, Wolf H, Wagner R; Institut fur Medizinische Microbiologie und Hygiene, Universitat Regensburg, Regensburg, Germany. Fax: +49 941 944 6402. Objective: In many viral infections, cell mediated immunity, in particular the cytotoxic T-cell response, plays a key role in the control of a viral infection. There is striking evidence to suggest that this may be also in the case of an HIV infection. Therefore we tested the capacity of different types of chimeric Pr5 |
| Mo.A.160 | Limited detection of HIV-1 subtypes by the Roche Amplicor Diagnostic polymerase chain reaction assay. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.160) Gleeson T, Montpetit M; HIV Genetics, Ottawa, Ontario, Canada. Fax: 613-957-7258. E-mail: mmontpetit@hpb.hwc.ca. Objective: To determine the effects of primer-template mismatches on Roche Amplicor Diagnostic polymerase chain reaction (PCR) results for HIV-1 strains not belonging to genetic subtype B. Methods: Computer analysis (OLIGSAN program) of homology between the Roche Amplicor PCR primer pair SK431/SK462 and 100 HIV-1 strai |
| Mo.A.161 | The effects of mutations on HIV-1 quantitation by RT/PCR. Int Conf AIDS 1996 Jul 7-12; 11:7 (abstract no. Mo.A.161) Christopherson CD, Kwok S; Roche Molecular Systems, Alameda, CA, USA. Fax: (510)814-2810. Primer design and amplification conditions were previously shown to effect 3 terminal mismatch tolerance (Kellog et. al., NAR 1990). In this study, we investigated the effect of internal primer-template mismatches on reverse transcription (RT)-PCR and of probe-template mismatches on probe capture efficiency. Templates |
| Mo.A.162 | Sensitive HIV antigen assay detecting HIV-1 group M, HIV-1 group O and HIV-2 core proteins. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.162) Louwagie J, Garrett PE, Mertens G, Van Geel A, Pollet D, van den Abeele A, Saman E; Innogenetics, Zwijdrecht, Belgium. Fax: 32 3 252 37 98. Objectives: To study the sensitivity and specificity of a newly developed antigen assay for the broad spectrum detection of HIV capsid antigens in human serum and to validate the confirmatory and immune complex dissociation reagents. Methods: The INNOTEST HIV Antigen mAb is a sandwich ELISA, based on a human immunoglob |
| Mo.A.163 | Use of synthetic peptides for differentiation between HIV 1 group M and group O, and for classification of group M (A - E) and group O strains into subtypes. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.163) Brust S, Knapp S, Gurtler LG; Behringwerke AG, Marburg, Germany. Fax: 49-6421-39-4680. E-mail: brust1@msmbwma.marburg.hoechst-ag.dbp.de. Objective: To develop synthetic peptide based immuno assays to differentiate between HIV 1 group M and group O infections. Furthermore to establish synthetic peptide based immuno assays suitable to classify Anti-HIV 1 positive sera into subtype A - E of group M and into different subtypes of group O. Methods: Relevant |
| Mo.A.164 | Sequencing HIV isolates using the GeneChip HIV PRT assay. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.164) Miyada CG, Liang V, Tran HM, Mittman M, Morris M, Kaplan P; Affymetrix, Inc., Santa Clara, CA, USA. Fax: 408-481-0422. E-mail: garry_miyada@affymetrix.com. Objective: To develop a fast method to accurately sequence HIV isolates using a novel method of hybridization to high-density arrays of oligonucleotide probes. Methods: The GeneChip HIV PRT Assay includes a high-density oligonucleotide array with probes complementary to the protease gene and 242 amino terminal residues |
| Mo.A.260 | Novel biological means of control of HIV and AIDS. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.260) Gallo RC; Institute of Human Virology, Medical Biotechnology Center, University of Maryland at Baltimore, Baltimore, MD, USA. Fax: 410-706-1952. E-mail: gallo@umbi.umdl.edu. 1) The C-C Cytokines (Rantes, MIP-1alpha, and MIP-1 ): These are a subset of chemokines which in turn are a subset of cytokines. Their known role was in inflammation. Last year we reported the discovery (Science, 270: 1560, 1995) that these molecules were potent inhibitors of HIV-1 and HIV-2 infection. We noted that th |
| Mo.A.270 | Plasma factors in human blood alter the entry and neutralization properties of HIV-1: implications for gp120-based vaccine approaches. Int Conf AIDS 1996 Jul 7-12; 11:8 (abstract no. Mo.A.270) Nara PL, Merges M, Wu SC, Spouge J; Virus Biology Section, LTCB, DBS, NCI-FCRDC, Frederick, MD. Fax: 301-846-6194. Conventional virology suggests one important aspect of viral tropism/pathogenicity is mediated by specific virus ligands interacting with specific cellular receptors. Factors, however, which govern and/or influence the specificity of these interactions within the host may involve colloidal or soluble molecules capable |
| Mo.A.271 | Removal of V3-specific antibodies from the serum of infected patients has minimal effect on neutralization of primary isolates of clade E HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.271) Stamatos NM, VanCott TC, Mascola J, Loomis LD, Louder M, Birx DL; Walter Reed Army Institute of Research, Rockville, MD. Fax: 301-762-4177. E-mail: nstamatos@HIV.hjf.org. Objective: To determine the role of V3-specific antibodies in mediating neutralization of primary clade E viral isolates. To compare these results with previous reports demonstrating a minimal role for V3-specific antibodies in neutralizing primary clade B viruses. Methods: Sera from 3 HIV-infected patients from |
| Mo.A.272 | Role of factor H in resistance of HIV against complement-mediated destruction. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.272) Stoiber H, Pinter C, Spruth M, Mullauer B, Clivio A, Manfred P; Dierich Institut fur Hygiene, Universitat Innsbruck, Insbruck, Austria. Objective: In the study, presented here, the binding site of complement factor H (CFH) to the HIV envelope was mapped and a new functional CFH polymorphism was analyzed Methods: The binding of CFH-derived peptides, covering the whole short consensus repeat (SCR) 13, to gp120 and gp41 was determined by ELISA and inhibit |
| Mo.A.273 | Cross-clade neutralization of HIV-1 by homologous and heterologous sera and identification of three isolates that predicts the neutralizing capacity of sera across HIV-1 clades. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.273) Nyambi PN, Lewi P, Nkengasong J, Janssens W, Fransen K, Peeters M, Willems B, Heyndrickx L, Andries K, Ndumbe P, van der Groen G; Institute of Tropical Medicine, Antwerpen, Belgium. Fax: 32 3 247 63 33. Objectives: To study the neutralization spectra of 14 sera and of 16 primary isolates of individuals infected with HIV-1 group M (subtype A-H) and group O. To identify a limited number of primary HIV-1 key isolates which allow to predict the neutralization spectrum of a serum. Methods: Serum (SNS) and isolate neutraliz |
| Mo.A.274 | Inactivation of HIV-1 by recombinant antibodies. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.274) Parren PW, Fisicaro P, Barbas CF 3d, Burton DR; The Scripps Research Institute, Dept of Immunology and Molecular Biology, La Jolla, CA, USA. Fax: (619) 554-6360. E-mail: parren@scripps.edu. Objective: To isolate broadly neutralizing recombinant antibodies to HIV-1 and characterize neutralization in vitro and in vivo. Methods: Antibody phage display libraries were prepared from long-term HIV-1 seropositve donors. In initial experiments, monomeric HIV-1 envelope subunits were used for enrichment and screeni |
| Mo.A.275 | Beta-chemokines inhibit HIV-1 entry into CD4+ cells via the C-C CKR-5 co-receptor. Int Conf AIDS 1996 Jul 7-12; 11:37 (abstract no. Mo.A.275) Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayana C, Maddon PJ, Koup RA, Moore JP, Paxton WA; The Aaron Diamond AIDS Research Center, New York, NY. Fax: (212) 725-1126. The beta-chemokines MIP-1alpha, MIP-1beta and rantes inhibit infection of CD4+ T-cells by primary, NSI HIV-1 strains at the virus entry stage, and also block env-mediated cell-cell membrane fusion. CD4+ T-cells from some HIV-1 exposed-uninfected individuals cannot fuse with NSI HIV-1 strains and secrete high levels of |
| Mo.A.280 | Phase I/II evaluation of candidate AIDS vaccines. Int Conf AIDS 1996 Jul 7-12; 11:9 (abstract no. Mo.A.280) Graham BS; Vanderbilt University School of Medicine, Nashville, TN, USA. Development of a preventive vaccine for AIDS. Project: The AIDS Vaccine Evaluation Group (AVEG) sponsored by NIAID consists of 6 University-based clinical testing sites, 2 central laboratories, a central data processing and analysis unit, and administrative support to select vaccine candidates, evaluate safety, |
| Mo.A.281 | HIV immunity induced by canarypox (ALVAC)-MN gp160,-SF2 rgp120 or both. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.281) Clements ML, Weinhold K, Siliciano R, Schwartz D, Matthews T, Graham B, Keefer M, McElrath J, Gorse G, Hsieh R, Duliege A, Excler J, Meigner B, Tartaglia J, Paoletti E; Center for Immunization Research, Baltimore, MD, USA. Fax: 410-550-6898. Objective: To evaluate the priming and boosting effect of two recombinant HIV vaccines. Methods: 106 and 107 TCID50 of recombinant canarypox (ALVAC)-HIVMN gp160 and 50 micrograms HIV-1SF2 rgp120 in MF59, were given i.m. to uninfected, vaccinia-naive and vaccinia-immune adults at 0, 1 or 2, 6 or 9, and 12 months. ALVAC- |
| Mo.A.282 | AVEU 022: safety and immunogenicity of live recombinant canarypox vector containing the envelope, gag and protease genes of HIV-1 in seronegative adult volunteers. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.282) Corey L, Weinhold K, McElrath J, Excler JL, Duliege AM, Clements ML, Belche R, Dolin R, Graham B; NIAID AVEU, Univ. of Washington, Pasteur Merieux Corp. and The Biocine Corp., Seattle, WA. Fax: 1-206-621-4178. E-mail: lcorey@u.washington.edu. Objective: To define the immunogenicity and safety of vCP205, a recombinant canarypox vaccine that expresses the P55 gag gene (LAI strain), P15 protease (LAI strain), gp120 (MN strain), and transmembrane region of gp41 (TM) (LAI strain). Methods: Seventy six seronegative (SN) volunteers at low risk of HIV infection, re |
| Mo.A.283 | Induction of potentially protective immunity in humans with a recombinant subunit HIV-1 vaccine. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.283) Francis DP, McElrath MJ, Berman PW, Belshe RB, Fast P; Genenvax, South San Francisco, CA, USA. Fax: 415-225-3957. E-mail: francis.don@gene.com. Objective: To induce protective immunity against HIV-1 using a safe vaccine. Methods: Two candidate vaccines, one from strain LAI and one from strain MN, consisting of envelope glycoprotein (gp 120) were produced in CHO cells using recombinant DNA technology. Chimpanzees vaccinated with these vaccines were intravenousl |
| Mo.A.284 | Safety, immunity, and risk behavior in HIV-1-uninfected volunteers representing diverse risk populations following recombinant envelope vaccinations: a three-year followup. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.284) McElrath MJ, Montefiori D, Wolff M, Clements M, Gorse G, Keefer M, Graham B, Duliege AM, Francis D, Matthews T, Fast P, Corey L; Univ of Washington, Seattle WA, USA. Fax: 1-206-621-4178. E-mail: kd@u.washington.edu. Objectives: Through the conduct of a phase II multicenter placebo-controlled double-blind vaccine trial in HIV(-) volunteers with either high or low HIV-1 risk behavior, to compare the clinical and immune responses, to determine the kinetics of HIV-1 neutralizing Ab responses after 4 immunizations, and to evaluate risk |
| Mo.A.285 | Genetic and immunologic characterization of viruses infecting MN-rgp120 vaccinated volunteers. Int Conf AIDS 1996 Jul 7-12; 11:10 (abstract no. Mo.A.285) Berman PW, Gray A, Ashby M, Eastman D, Wrin T, Vennari JA, Francis D, Gregory T, Fast P, Schwartz D, Gorse G, McElrath MJ; Genetech, Inc., South San Francisco, CA. Fax: (415) 225-2006. Objective: To determine whether individuals who acquired HIV-1 infections, through high risk behavior, during vaccine safety and immunogenicity studies, were infected by viruses with envelope glycoproteins that resembled the vaccine immunogen, MN-rgp 120. Methods: 10 of 507 adults participating in Phase I and II vaccin |
| Mo.A.380 | Enhanced fidelity of 3TC-selected M184V HIV reverse transcriptase. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.380) Wainberg MA, Hsu M, Gu Z, Inouye P, Quan Y; McGill University AIDS Centre-Jewish General Hospital, Montreal, Quebec, Canada. Fax: 514-340-7537. E-mail: mdwa@musica.mcgill.ca. Objective: To determine the basis of success of 3TC in recent clinical trials that have reported increased CD4 counts and diminished viral burden. Specifically, we asked whether these findings might be attributable to an increase in fidelity of HIV reverse transcriptase conferred by the M184V substitution responsible f |
| Mo.A.381 | Mutations associated with 3TC-resistance enhance the polymerase fidelity of HIV-1 RT. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.381) Prasad VR, Drosopoulos W; Dept. of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY, USA. Fax: 718-430-8711. E-mail: Prasad@aecom.yu.edu Vinayaka. Objective: To determine whether mutations associated with 3TC-resistance confer an increased polymerase fidelity to HIV-1 reverse transcriptase. Methods: Recombinant wild type, Met184Val, Glu89Gly and Met184Val/Glu89Gly HIV-1 RT heterodimers were purified. These RTs were assayed in vitro, with model template-primers, f |
| Mo.A.382 | In vivo evidence for modulation of HIV-1 dynamics by target cell availability and cellular immunity. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.382) Goudsmit J, De Wolf F, Lukashov VV, Van Oers RH, Bakker M, Boucher CA, Danner SA; Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Fax: 31-20-6916531. Objective: To assess the role of availability of HIV-1 susceptible cells and T cell immunity in the maintenance of HIV-1 steady-state levels during infection. Materials and Methods: Two late stage HIV-1 infected male homosexuals received two syngeneic bone marrow transplants (BMT) each, one with and one without prior h |
| Mo.A.383 | Retroviral fitness and drug selection pressure. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.383) Harrigan PR, Bloor S, Nowak M, Larder BA; Clinical Virology, Beckenham Kent, UK. Objective: To quantitate the effects of mutations conferring resistance to antiretrovirals such as zidovudine ( AZT ) on viral fitness and drug selection pressure. To allow estimation of steady state levels of given viral variants and patterns of development of drug resistance. Methods: Cultures of defined mixtures of |
| Mo.A.390 | Determinants of long-term non-progression: the relative contribution of viral burden and strain variation. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.390) Sheppard HW, Krowka J, Ascher M, Cuevas B, Dondero D, Lu E; Viral and Rickettsial Disease Laboratory, Calif. Dept. Health Services, Berkeley, CA, USA. Fax: (510)540-2127. E-mail: hsheppar@HIVnet.fhcrc.org. Objective: To determine the relative contribution of virus burden and virus strain variation to differences in the rate of progression from HIV-1 infection to AIDS. Do long-term non-progressors harbor attenuated strains of HIV-1? Methods: Longitudinal studies of virus burden (measured as cellular provirus or plasma RNA |
| Mo.A.391 | HIV-1-specific cytotoxic T lymphocyte and proliferative responses in peripheral blood mononuclear cells (PBMC) of subjects with stable non-progressing HIV-1 infection. Int Conf AIDS 1996 Jul 7-12; 11:11 (abstract no. Mo.A.391) Kalams SA, Harrer T, Harrer E, Billingsly M, Trocha AK, Shea A, Jones N, Hartman KE, He S, Johnson RP, Buchbinder SP, Walker BD; MGH-East, Charlestown, MA, USA. Fax: (617) 726-5411. Objective: To determine the immune correlates of long-term non-progression in HIV-1 infected subjects Methods: Long term non-progressors were asymptomatic gay men with CD4 counts greater than 500 cells/mm3, and a duration of infection of longer than 10 years. Control subjects were infected less than 7 years and had CD4 |
| Mo.A.392 | Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in individuals without clinical progression. Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.392) Lubaki MN, Dhruva B, Quinn TC, Siliciano RF, Bollinger RC; Johns Hopkins University, Ross Research Building, Baltimore, MD. Fax: 410-955-7889. E-mail: NLUBAKI@WELCHLINK.WELCH.JHU.EDU. Objective: To characterize a detailed clonal analysis of the cytolytic T lymphocyte (CTL) response to HIV-1 in two individuals who have been infected with HIV-1 for greater than 10 years and have maintained an absolute CD4 counts of greater than 800 cells/mm3. Methods: HIV-1-specific CTL activity was measured in fresh |
| Mo.A.393 | Immunological studies on the french cohort of 70 HIV-1-infected long-term non progressors (LTNP). Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.393) Hadida F, Bonduelle O, Candotti D, Bouley JM, Costagliola D, Agut H, Rouzioux C, Goubar A, Clauvel JP, Sicard D, Autran B; Laboratoire D'Immunologie Cellulaire, Paris, France. Fax: (33 1) 42 17 74 90. Objective: To study the immunological parameters associated to the LTNP status with special regards for the CD4+ T helper cell reactivity to HIV. Methods: A cohort of 70 LTNP was recruited in 1994 on the following criteria: infection for at 8 years, positive or null CD4 T cell slope for the last 5 years above 600/mm3, |
| Mo.A.394 | HIV phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.394) Clerici M, Balotta C, Salvaggio A, Riva C, Trabattoni D, Papagno L, Berlusconi A, Rusconi S, Villa ML, Moroni M, Galli M; Cattedra di Immunologia, Universita degli Studi di Milano, Milano, ITALY. Fax: 39-2-3821-0350. E-mail: mago@imiucca.csi.unimi.it. Objective: To establish possible correlations between virologic and immunologic markers of protection and progression in HIV-infected individuals. Methods: We cross-sectionally analysed the rate and extent of HIV replication; HIV phenotype; in vitro-stimulated cytokine production [interferon gamma and interleukin-2 (ty |
| Mo.A.395 | Microsatellite polymorphisms of the human TNF locus are associated with the rate of HIV disease progression. Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.395) Khoo SH, Pepper L, Snowdon N, Wilkins EG, Valleley P, Ollier W; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK. Background: The rate of immunological deterioration and progression to AIDS differs markedly between HIV-positive individuals, and may be influenced by cofactors, HIV phenotype and the host T-cell response. Production of TNFalpha stimulates viral replication and may accelerate progression and CD4 depletion. MHC polymor |
| Mo.A.400 | SIV-superinfection immunity in macaques is influenced by the dose of attenuated virus. Int Conf AIDS 1996 Jul 7-12; 11:12 (abstract no. Mo.A.400) Sharpe SA, Whatmore AM, Cook N, Polyanskaya N, Hall G, Rud E, Stott EJ, Cranage MP; CAMR, Porton Down, Salisbury, Wilts, United Kingdom. Fax: 44 1980 611310. Objective: To determine if the dose of live attenuated SIVmac used to immunise macaques influences the outcome of subsequent challenge with virulent, non-clonal virus. Methods: Ten rhesus macaques were inoculated with the SIVmac molecular clone C8, which has an attenuated phenotype in vivo due to a 12bp in-frame deleti |
| Mo.A.401 | Immune parameters among highly exposed, persistently seronegative (HEPS) Thai women. Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.401) Rungruengthanakit K, Duerr A, Suriyanon V, Flowers L, Nagachinta T, Tansuhaj A, Kunangern D, de Boer M, Nelson KE; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand. Fax: 66 53 221849. Objective: To investigate immunologic parameters associated with lack of sexual transmission of HIV to women despite repeated exposure to a single HIV-infected (HIV+) partner. Methods: Highly exposed persistently seronegative (HEPS) women were selected from an ongoing study of HIV transmission from HIV-infected (HIV+) |
| Mo.A.402 | Are high-risk HIV-seronegative Zambian women resistant or just lucky? Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.402) Krowka JF, Allen S, Weinstein S, Santamaria C, Cuevas B, Gestner M, Sheppard H; California Dept. of Health Services, Berkeley, CA, and UCSF, San Francisco, CA. Fax: 510-540-2579. E-mail: SFJOHNK1@AOL. COM. Objective: To determine if T cell responses play a role in preventing infection of high-risk HIV-seronegative (HIV-) Zambian women. Methods: Blood from matched high-risk (married to HIV+ men) and low-risk HIV- Zambian women were analyzed to compare peripheral blood lymphocyte (PBL) proliferative responses to Candida, a |
| Mo.A.403 | Superinfection of HIV-2-infected pigtail macaques using two distinct isolates: identification of a window period for susceptibility. Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.403) Otten RA, Ellenberger DL, Adams DR, Fridlund CA, Jackson E, Schochetman G, Rayfield MA; HIV Laboratory Investigations Branch, DASTLR, NCID, CDC, Atlanta, GA, USA. Fax: (404)639-1010. E-mail: rxol @ciddas1.em.cdc.gov. Objective: To establish and study homotypic mixed infections with two phenotypically and genotypically distinct primary isolates of HIV-2 using an established animal modeling system for human retroviral infection. Methods: Challenge stocks (102 macaque infectious doses) for a high syncytia-forming isolate from |
| Mo.A.404 | Immune correlates of protection in HIV vaccine efficacy trials in nonhuman primates. Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.404) Heeney JL, Bogers WM, Mooij P, Teeuwsen V; Biomedical Primate Research Centre, Rijswijk, The Netherlands. Fax: +31-15-2843986. E-mail: heeney@bprc.nl. Objectives: To determine the nature of HIV-1 vaccine induced immune responses which correlate with protection from homologous as well as heterologous challenge with different isolates of HIV-1 in chimpanzees and SHIV in rhesus monkeys respectively. Methods: Within the ECCF programme a comparison of immune responses was |
| Mo.A.405 | Antagonism of vaccine-induced HIV-specific CD4+ T cells by primary HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:13 (abstract no. Mo.A.405) Kent SJ, Greenberg P, Hoffman M, Corey L, McElrath MJ; Macfarlane Burnet Centre for Medical Research, Fairfield, Australia. Fax: + 61 3 9482 6152. E-mail: kent@burnet.mbcmr.unimelb.edu.au. Objective: Defining immune responses to HIV-1 vaccines which lead to favorable or unfavorable outcomes upon HIV-1 exposure will ultimately improve HIV vaccine design. Methods: T helper (Th) cell responses to HIV-1 were cloned and analyzed in a recipient of a candidate HIV-1 vaccine who subsequently became infected with |
| Mo.A.406 | Induction of primary isolate-neutralizing antibodies by candidate HIV-1 vaccines. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.406) Zolla-Pazner S, Berman P, Gregory T, Robert-Guroff M, Natuk R, Sinangil F, Steimer K; V.A. Hospital, New York, NY, USA. Fax: 212-951-6321. E-mail: ZOLLASo1@MCRCR6.MED.NYU.EDU. Objective: To determine if antibodies (Abs) that neutralize HIV-1 primary isolates are induced in chimpanzees and humans immunized with various candidate HIV-1 vaccines. Methods: Coded panels of sera from HIV-infected humans and from uninfected humans and chimpanzees immunized with various HIV-1 vaccines were tested fo |
| Mo.A.500 | Stimulation of HIV-1 LTR-directed transcription by the ras pathway requires the novel transcription factors RBF-1 and RBF-2. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.500) Bell B, Sadowski I; Department of Biochemistry and Molecular Biology, UBC, Vancouver, B.C., Canada. Fax: (604) 822-5227. E-mail: brbell@unixg.ubc.ca. Objective: We sought to determine the cis-acting DNA sequences necessary for the stimulation of HIV-1 transcription in response to the Ras signal transduction pathway in Jurkat T cells. Methods: We used cotransfection of activated Ras alleles with HIV-LTR-CAT reporter contructs to map the cis-acting DNA sequences essen |
| Mo.A.501 | Regulation of HIV transcription in T cells and macrophages: critical role of NF-kB activation, and its control by nuclear IkBalpha. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.501) Virelizien JL, Alcami J, Arenzana-Seis dedos F, Italy RT; Concerted Action ("R'ocio" project) of Eu Biomed programme, and Unite d'Immunologie Virale, Institut Pasteur, Paris, France. Objective: How HIV uses the environment of T cells and macrophages to benefit its own latency and replication needs to be understood to better adapt future antiviral interventions to the original strategy of this human lentivirus. Project: A network of European laboratories (project ROCIO, Concerted Action of the BIOME |
| Mo.A.502 | Cloning of a novel human protein that regulates NF-kB activity and delineation of phosphorylation events on Sp1: implications for HIV-1. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.502) Jin DY, Chun RF, Jeang KT; Molecular Virology Section, LMM, NIAID, NIH, Bethesda, MD, USA. Fax: (301) 402-0226. E-mail: kj7e@nih.gov. Objective: To characterize the direct effector mechanisms that activate HIV-1 LTR transcription factors Sp1 and NF-kB by identifying novel regulatory second messengers and phosphorylation events. Methods: cDNA libraries were screened to identify a novel human antioxidant (AOE372). Full-length sequence of this cDNA was |
| Mo.A.503 | Transdominant mutants of IkBalpha interfere with HIV-1 gene expression and replication. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.503) Hiscott J, Lin R, Beauparlant P, Kwon H, Clarke M, Gessani S, Belardelli F, Wainberg M; Lady Davis Institute, Montreal, Quebec, Canada. Fax: 514-340-7576. E-mail: MIJH@MUSICA.McGILL.CA. Objectives: NF-kB/Rel transcription factors participate in the coordinate activation of HIV-1 and cytokine gene expression. In the present study, transdominant negative mutants of IkBalpha were examined for their ability to interfere with Tat-TNF activation of the HIV-1 LTR and HIV-1 replication. Methods: Point mutatio |
| Mo.A.510 | Survey on HIV-1 group O infection in 12 different African countries. Int Conf AIDS 1996 Jul 7-12; 11:14 (abstract no. Mo.A.510) Peeters M, Mboup S, Gueye A, Liegeois F, Patrel D, Vanden Haesevelde M, Delaporte E; Service de Bacterio - virologie Hopital de Dantec B.P., Dakar, Senegal. Fax: 22121 64 42. Objective: To determine to what extend HIV-1 group O strains are present in different African countries Materials and Methods: 11985 sera from 12 different African countries were tested ( Senegal , Mali , Togo , Burkina Faso , Niger , |
| Mo.A.511 | HIV-1M diversity analysed by serological subtyping: what assay, what antigens, significance? Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.511) Barin F, Plantier JC, Buzelay L, Poisson F, Simon F, Peeters M; laboratoire de Virologie, CHU Bretonneau, France. Fax: (33) 47473610. Objective: To develop performing assays for serological subtyping of HIV-1M infection and determine their value for epidemiological studies of HIV-1M diversity. Methods: We synthesized 30 aa long peptides representing the consensus sequences of the V3 regions from I) 8 subtypes defined by genetic analysis (Myers et al, |
| Mo.A.512 | Detection of incident HIV infection using a reflex algorithm of laboratory testing methods. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.512) Galli RA, Major C, Fearon M, Swantee C, Francis A, Gregory B; HIV Laboratory, Ontario Ministry of Health, Etobicoke, Ontario, Canada. Fax: (416) 235-6194. Objective: To examine the efficacy of a laboratory testing algorithm for detection of incident cases of HIV in a population with varying exposure categories, with particular focus on the window period of infection. Methods: A retrospective analysis of the results of 256,265 specimens that were applied to a laboratory a |
| Mo.A.513 | Multicentre evaluation of alternative methods for CD4 lymphocyte determination. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.513) Lyamya EF, Schechter M, Echeverria de Perez G, Vercauteren G; Department of Microbiology/Immunology, Muhimbili Medical Centre, Dar es Salaam, Tanzania. Fax: +255 51 44 544. Objective: To evaluate the performances of four simpler and cheaper alternative methods for CD4 lymphocyte determination as compared to the reference method, (flow cytometry) in less-industrialized countries ( Brazil , Tanzania , Venezuela ). Methods: The performance of the FACScount (Becton Dicki |
| Mo.A.520 | HIV-1 secreted viral antigens(SVA), polyphosphazene adjuvant, and SHIV challenge model. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.520) Lu Y, Touzjian N, Kushner N, Chutkowski C, Qian H, Jenkins S, Payne L, Roberts B; Virus Research Institute, Cambridge, MA, USA. Fax: 617-864-6334. E-mail: 72054.701@compuserv.com. Objective: To evaluate the efficacy of novel HIV-1 vaccine formulations composed of secreted viral antigens plus a unique adjuvant in rhesus monkeys. Methods: 1) HIV-1 SVA are prepared from a fibroblast cell line that is transformed with a genetically engineered HIV-1 provirus that is able to express all major viral pr |
| Mo.A.521 | Immunogenicity of modified, recombinant HIV-1 virus-like particles in rhesus monkeys. Int Conf AIDS 1996 Jul 7-12; 11:15 (abstract no. Mo.A.521) Wagner R, Teeuwsen V, Deml L, Heeney J, Wolf H; Inst. of Medical Microbiology, University of Regensburg, Germany. Fax:.49 941 944 6402. E-mail: Ralf. Wagner@klinik.uni.rejensburg.de. Objective: To develop a safe antigen delivery systems, which contributes towards defining the role of different arms of the immune system, that confer protection Methods: When expressed in insect cells, the HIV group specific antigen (gag) self assembles to highly immunogenic virus-like particles (VLP). The immunogenic |
| Mo.A.522 | Induction of HIV-1 nef specific CTLs by nef expressing DNA vaccine. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.A.522) Asakura Y, Hamajima K, Fukushima J, Kaneko T, Tsuji T, Sasaki S, Bukawa H, Mohri H, Ohkubo T, Okuda K; Yokohama City University, Yokohama, Japan. Fax: 81-45-787-2509. Objective: Recent studies have revealed the importance of HIV-1 specific CTLs for preventing the establishment of infection and prolongation of entire clinical course in the infected individuals. Among many epitopes of HIV-1 CTL determinants, Nef is thought to be one of the essentials in preventing the establishment of |
| Mo.A.523 | Induction of immune responses by DNA of HIV-1 regulatory and structural genes. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.A.523) Wahren B, Hinkula J, Benthin R, Lundholm P, Svanholm C, Okuda K, Schwartz S; MTC, Karolinska Institute, Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Fax: +46-8-272231. Objectives: We aim to induce immunity to HIV by vaccination with regulatory and structural genes. Methods: The selected genes of HIV-1 tat, nef, rev, envelope gp160 and nucleoprotein were transactivated by the human cytomegalovirus promoter IE and named pHCMVsrev, pHSCVtat, pHCMVnef, pCMVgp160 and pCMVp37gag. Intramusc |
| Mo.B.110 | Persistent oral ulcers in HIV infection: clinicopathologic correlation with salivary human herpes viruses. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.B.110) Flaitz CM, Boldogh I, Nichols CM, Albrecht T; Department of Stomatology, Dental Branch, University of Texas-Houston Hlth Sci Ctr, Houston, TX. Fax: 713-792-2383. Objective: The purpose of this prospective study was to characterize the clinical and histopathologic features of persistent oral ulcers (POUs) in HIV infection and correlate these findings with various human herpes viruses (HHVs) in saliva. Methods: Sixty-two consecutive HIV-positive patients with POUs (duration great |
| Mo.B.111 | A long-term randomized controlled clinical trial comparing fluconazole and itraconazole in the treatment of AIDS patients with candida esophagitis. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.B.111) Barbaro G, Grisorio B, Calderon W, Di Lorenzo G, Barbarini G; Clinic of Infectious and Tropical Diseases IRCCS, S. Matteo University of Pavia, Pavia, Italy. Fax: 39-382-423320. Introduction: Contrasting opinions exist about the pharmacological treatment of esophageal candidiasis in HIV-positive patients and little information is actually available regarding the response of Candida esophagitis to antifungal therapy. Aim of the study has been to assess the long-term therapeutic efficacy of fluc |
| Mo.B.112 | Fluconazole resistant mucosal candidiasis in advanced HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:16 (abstract no. Mo.B.112) Fichtenbaum CJ, Koletar S, Yiannoutsos C, Chen D, Cohn S, Pottage J, Powderly W; Fax: 314-361-5231. E-mail: fichtenbaum@visar.wustl.edu. Objective: To define the epidemiology of fluconazole resistant candidiasis in advanced HIV infection. Methods: ACTG 816 is a prospective, multicenter observational study of the incidence, risk factors and outcome of resistant mucosal candidiasis in HIV-infected persons with CD4+ lymphocyte counts less than 100 cells/mm |
| Mo.B.113 | Complications in gastrointestinal CMV disease-prevalence, characteristics and clinical outcome. Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.113) Heise W, Arasteh K, Mostertz P, Schmidt W, Biniek B, Grosse G, L'age M; Auguste-Viktoria-Hospital, Berlin, Germany. Fax: 0049-30-7903 2005. Objective: To determine the prevalence of life-threatening complications such as bleeding, perforation or obstruction in Cytomegalovirus ( CMV ) gastrointestinal(GI) disease in AIDS. Methods: CMV disease in the GI tract was diagnosed in 257 symptomatic patients with AIDS. Life-threatening complications were defined as |
| Mo.B.114 | Clinical manifestations, extraintestinal complications and long-term course of intestinal Enterocytozoon bieneusi microsporidiosis. Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.114) Briner D, Meister TH, Luthy R, Weber R; Division of Infectious Diseases, University Hospital of Zurich, Zurich, Switzerland. Fax: 41-1-255 32 91. Objective: To determine the clinical manifestations, complications, and the long-term course of E. bieneusi-infection. Methods: 55 HIV+ patients (5 women, 50 men) with E. bieneusi-infection were studied. Patients were prospectively followed in the ongoing Swiss HIV cohort study (SHCS) which included the evaluation of p |
| Mo.B.115 | Prospective evaluation of the clinical significance of intestinal microsporidiosis in 2 cohorts of HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.115) Albrecht H, Sobottka I, Ziellmann M, Meyer S, Jackle S, Stellbrink HJ, Greten H; University Clinic Eppendorf, Hamburg, Germany. Fax: xx49-40-47175187. E-mail: albrecht@uke.uni-hamburg.de. Objective: To determine the clinical significance of intestinal microsporidiosis in two different cohorts of HIV-infected patients and to compare the sensitivity and specificity of different diagnostic methods. Methods: Two prospective studies were performed: a) Between November 1993 and September 1994 stool samples of |
| Mo.B.116 | Itraconazole oral solution (IS) compared with fluconazole (F) for treatment of esophageal candidiasis (EC). Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.116) Moskovitz BL, Wilcox CM, Darouiche R, Wu J, Mallegol I; Janssen Research Foundation, Titusville, NJ. Fax: 609-730-3044. Objective: To demonstrate comparable safety and equivalent efficacy of IS, a cyclodextrin formulation with greater bioavailability than itraconazole capsules, to F for treatment of EC in immunocompromised patients. Methods: This was a double-blind, double-dummy study. Patients were randomized equally to IS or F, 100-20 |
| Mo.B.117 | Itraconazole oral solution (IS) for the treatment of oropharyngeal candidiasis (OC): results of two randomized, blinded studies. Int Conf AIDS 1996 Jul 7-12; 11:17 (abstract no. Mo.B.117) Darouiche RO, Graybill JR, Vazquez J, Murray P, Wu J, Moskovitz BL; VA Medical Center, Houston, TX, USA. Fax: 713-794-7045. Objective: To compare the safety and efficacy of IS (cyclodextrin formulation) with clotrimazole and fluconazole (F) in HIV+ patients (pts) with OC. Patients: Study 1 (IS vs C) = 162 total pts enrolled, 134 HIV+ enrolled, 123 HIV+ evaluated; Study 2 (IS vs F) = 190 HIV+ pts enrolled, 179 evaluated; all pts evaluated ha |
| Mo.B.118 | Gastric hypochlorhydria is associated with mycobacterium avium complex (MAC) infection in patients with HIV/AIDS. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.118) Koch J, Scott MK, Morgan D, Steuerwald M, Lor E, Cello JP; Div. of GI, San Francisco General Hospital, San Francisco, CA. Fax: 415-641-0745. E-mail: hannes@itsa.ucsf.edu. Purpose: To determine the association between gastric hypochlorhydria and MAC infection in patients with HIV/AIDS. Methods: Evaluation of gastric fluid aspirate in patients with HIV/AIDS (study group) and patients not HIV-infected (control group) undergoing elective endoscopy (off all proton pump inhibitors and histami |
| Maintenance of long-term virus suppression in patients treated with the HIV-1 protease inhibitor Crixivan (indinavir). Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.170) Emini EA, Condra JH, Schleif WA, Massari FE, Leavitt RY, Deutsch PJ, Chodakewitz JA; Merck Research Laboratories, West Point, PA, USA. Fax: 215-652-0994. E-mail: emilio_emini@merck.com. Objective: Loss of Indinavir-mediated virus suppression seen in some patients during treatment with the inhibitor has been shown to be associated with the selection of viral variants expressing reduced Indinavir susceptibility. However, the apparent probability and timing of resistant virus selection varies widely amon |
|
| Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.171) Sun E, Heath-Chiozzi M, Cameron DW, Hsu A, Granneman RG, Maurath CJ, Leonard JM; Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL, USA. Fax: 847-938-3711. E-mail: sune@randb.abbott.com. Rifabutin is used for the prophylaxis and treatment of MAC infection in AIDS patients. Dose-related side effects include uveitis, skin discoloration, and arthralgia/arthritis.1 Ritonavir (ABT-538) is a potent inhibitor of the HIV protease, and has demonstrated clinical and virologic efficacy in a placeb |
|
| Efficacy and safety of triple combination therapy with Invirase (saquinavir/SQV/HIV protease inhibitor), Epivir (3TC/lamivudine) and Retrovir (ZDV/zidovudine) in HIV-infected patients. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.172) Baruch A, Mastrodonato-Delora P, Schnipper E, Salgo M; Hoffmann-La Roche, Nutley, New Jersey. Fax: (201) 812-3629. Objective: To provide activity and safety data for SQV in combination with ZDV and 3TC Methods: A total of 33 HIV+ patients, naive to antiretroviral therapy and with CD4 counts 150-500 cells/mm3 were enrolled in an exploratory, single arm open-label study of combination treatment with SQV 600 mg tid, 3TC 150 mg bid and |
|
| Extended follow-up of safety and activity of agouron's HIV proteinase inhibitor ag1343 (Viracept) in virological responders from the UK phase I/II dose finding study. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.173) Moyle GJ, Youle M, Higgs C, Monaghan J, Peterkin J, Chapman S, Nelson M; Kobter Centre, Chelsea And Westminister Hospital, London, UK. Fax: UK 171 938 3460. Introduction: In the first 28 day open-label phase I/II dose escalation trial with AG1343, HIV-positive therapy naive persons, with baseline CD4 200-500 cells/mm3 and viral loads greater than or equal to 20000 copies/ml (by bDNA) were treated with doses of 771 (N=10) and 1026 mg (base equivalent)/day (N=10) of AG1343 [ |
|
| Indinavir (MK 639) drug interaction studies. Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Mo.B.174) McCrea JB; Clinical Pharmacology, Merck Research Laboratories, West Point, PA, USA. Fax: 610-834-0213. Objective: To evaluate potential pharmacokinetic interactions between indinavir (MK 639; IDV) with drugs that are P-450 3A substrates and/or with drugs that are frequently prescribed to HIV-infected patients. Methods: Seven studies used a 3-period crossover design: IDV given alone, in combination with the other drug of |
|
| A triple combination of Ritonavir+AZT+ddC as a first line treatment of patients with AIDS: update. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.175) Mathez D, Bagnarelli P, De Truchis P, Gorin I, Katlama C, Pialoux G, Ruggeri C, Saimot AG, Tubiana R, Chauvin JP, Clementl J, Leibowitch J; Hopital Raymond Poincare, Garches, France. Objective: To combine one potent HIV-1 protease inhibitor with 2 synergistic nucleoside analogues in treatment-nave patients with advanced HIV infections. Patients and methods: 29 virus-culture positive HIV-1 infected adults with less than 250 CD4/microgram 1 were offered an ethical review board-approved open label com |
|
| Evaluation of the safety and efficacy of SPV-30 (boxwood extract) in patients with HIV disease. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.180) Pharo A, Salvato P, Thompson C, Stokes D, Mastman B, Keister R; Twelve Oaks Hospital, Houston, TX. Fax: (713) 960-7910. Objective: To determine if SPV-30, an all natural boxwood evergreen extract, manufactured by Arkopharma in France is safe and efficacious in HIV disease. Methods: HIV-1 viral load measured by RNA PCR and dDNA, CD4 counts and CD8, counts were evaluated in 173 HIV patients. Baseline viral load ranged from virtually no HI |
|
| Nationwide longitudinal outcomes study of HIV/AIDS alternative therapies. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.181) Standish LJ, Calabrese C, Reeves C; Bastyr University AIDS Research Center, Seattle, WA, USA. Fax: 206-517-3599. E-mail: ljs@bastyr.edu. Objective: The Bastyr University AIDS Research Center was established in October 1994 by the NIH s Office of Alternative Medicine. The mission of the Center is 1) to describe forms and patterns of use of alternative medical (AM) therapies for the treatment of HIV+ patients, either prescribed by practitioners or self-ad |
|
| Mo.B.182 | A standardized clinical assessment tool on the use of alternative therapies by HIV-positive individuals. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.182) Sabo CE, Paterson MA, Carwein VL; University of Nevada, Las Vegas, College of Health Sciences Las Vegas, NV. Fax: 702-895-1356. E-mail: csabo@ccmail.nevada.edu. There is currently no standardized clinical tool to assess the use of alternative therapies in HIV-positive individuals. Project: A tool which can be used to assess the use of alternative therapies in HIV-positive individuals is developed based on a survey of 127 HIV-positive individuals who used alternative the |
| Mo.B.183 | Use of alternative treatments for HIV: patterns and correlates. Int Conf AIDS 1996 Jul 7-12; 11:19 (abstract no. Mo.B.183) Collins RL, Kanouse DE, Senterfitt JW, McCutchan AJ, Wenger NS, Fleishman JA, Marshall GN, Kelly MD, Grant I, Bozzette SA; RAND, Santa Monica, CA, USA. Fax: (310) 451-6917. E-mail: RebeccaCollins@rand.org. Objective: To determine the extent to which those who use alternative treatments fail to disclose this to medical providers or substitute these treatments for more conventional therapies, and to identify correlates of these behaviors. Methods: One hundred forty HIV+ persons being followed at the UCSD Neurobehavioral Re |
| Mo.B.184 | Evolving strategic planning in complementary therapies: a national care, treatment & support approach. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.184) Bhatia R, McDonald J; Health Canada, HPSB, AIDS Care, Treatment Division, Ottawa, Ontario, Canada. Fax: 613-941-3526. In North America, upwards of 70% of HIV-positive persons make use of complementary therapies. In Canada , few resources have been committed and little done to take a national approach to the use and place of complementary therapies in HIV/AIDS treatment. Project: In November of 1995 the AIDS Care, Treatment and |
| Mo.B.190 | A training program to enhance nurses' clinical assessment of HIV patients via standardized procedures. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.190) Katsufrakis PJ, Hummel D, Saunders JM, Nyquist JG; Pacific AIDS Education and Training Center, University of Southern California, Los Angeles, CA. Fax: (213)342-2663. Nurses approach to health promotion, symptom management and integrated care is needed by patients with HIV. This program increases nursing participation in primary care of HIV/AIDS patients, necessary in the face of increasing numbers of patients, inadequate access to care, and burnout of existing providers. Pro |
| Mo.B.191 | Who is serving whom: the challenge of continuity and customer service. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.191) Veldhorst G, Grondin M, Harrison H; The Wellesley Hospital, Toronto, Ontario, Canada. Fax: 416-926-7924. People living with HIV receiving care at a medium sized teaching hospital were concerned that the traditional models in which nursing care was delivered was not satisfactorily meeting their needs. Frequent interactions with the health care system and the complex physical manifestations affecting the body, mind a |
| Mo.B.193 | Knowledge and attitudes regarding HIV infection among auxiliary nurses working at IMIP's hospital. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.193) Araujo WS, Souza E, Santos R, Mendonca K, Cantarutti L; Instituto Materno Infantil de Pernambuco (IMIP), Recife, Pernambuco, Brazil. Fax: 55-81-2226591. Objective: To determine the current knowledge and attitudes of auxiliary nurses (AN) working at Instituto Materno Infantil de Pernambuco s (IMIP) Hospital, reference center for mother and child health and HIV infection in children, in a cross-sectional study. Methods: On July 1995, 100 out of 400 AN working at IMIP wer |
| Mo.B.194 | Continuity of nursing care in an HIV outpatient clinic. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.194) Wilkinson M, Pullen S, Phillips M; Grahame Hayton Unit, Ambrose King Centre, Royal London Hospital, England, UK. Project: To implement a system providing continuous care by the same nurse throughout a patient s stay in the clinic. The nursing staff comprised of three registered general nurses, all with post-registration HIV training and varying levels of both general and HIV nursing and research experience. A total of 344 patient |
| Mo.B.195 | Health care personnel education on AIDS. Int Conf AIDS 1996 Jul 7-12; 11:20 (abstract no. Mo.B.195) Simpson C, Augustine J; C.M.C. Hospital, Vellore, India. Issues: Nursing personnel have irrational fear towards AIDS Care. Projects: Education plays a major role in prevention of HIV infection and enhancement of compassionate care to AIDS patients. Hence, inservice education was arranged in all the clinical departments, by the supervisor. Protocols on AIDS care was prepared |
| Mo.B.196 | Outcomes of an undergraduate HIV/AIDS nursing elective: insightful learning to promote quality care. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.196) Wyness MA, Goldstone I, Trussler T; University of British Columbia, Vancouver, BC, Canada. Fax: (604) 822-7466. E-mail: wyness@nursing.ubc.ca. Research has shown that nursing students knowledge about HIV/AIDS is frequently inadequate and that fostering the values, attitudes, skills and professional confidence required to provide quality nursing care is the major challenge for educators. Project: An undergraduate HIV/AIDS elective was developed in colla |
| Mo.B.290 | Effect of nucleoside analogue RT inhibitors on plasma HIV RNA and CD4 count as an indicator of clinical effect. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.290) Phillips AN, Eron J, Bartlett J, Hill AM; HIV Research Unit, Dept. Primary Care and Population Sciences, Royal Free Hospital School of Medicine, London, UK. Fax: UK 171-794-1224. E-mail: andrew@rfhsm.ac.uk. Objective: To assess the extent to which the effect of combination therapy with zidovudine + lamivudine ( 3TC ) on plasma HIV RNA and the CD4 count is translated into a clinical effect. Methods: For 620 patients randomised in the North American NUCA3001 (n=366; zdv/3TC vs zdv vs 3TC in zdv nai |
| Mo.B.291 | A randomized, comparative trial of ZDV versus ZDV plus ddI versus ZDV plus ddC in persons with CD4 cell counts of less than 200/mm3. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.291) Saravolatz LD, Collins G, Hodges D, Winslow D, Pettinelli C; Infectious Diseases Division, Henry Ford Hospital, Detroit, MI. Fax: (313) 876-2993. Terry Beirn Community Programs for Clinical Research on AIDS 007 Protocol Team, NIAID, Bethesda, Maryland, USA Objective: To compare the efficacy of zidovudine (ZDV) alone, ZDV given with didanosine (ZDV + ddI ), and ZDV given with |
| Mo.B.292 | HIV viral load changes in delta patients. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.292) Brun-Vezinet F; Laboratoire de Virologie, Hopital Bichat, Paris, France. Fax: 33 1 46 27 02 08. Objective: To study correlation between viral load changes, immunological evolution and clinical outcome in a subset of Delta 1 AZT-naive patients. Methods: A total of 230 patients were recruited in 22 selected centers in France , UK and Netherlands for virological studies including viral load quantitation. |
| Mo.B.293 | Suppression of plasma HIV RNA by reverse transcriptase inhibitors prevents AIDS and death in ACTG 175; combination and monotherapy with ZDV, ddI and ddC. Int Conf AIDS 1996 Jul 7-12; 11:21 (abstract no. Mo.B.293) Katzenstein DA, Hammer S, Hughes M, Gundacker H, Jackson B, Fiscus S, Lathey J, Rasheed S, Reichman R, Elbeik T, Japour A, D'Aquila R, Scott W, Griffiths B, Winters M, Merigan T, Hirsch M; Stanford University Medical Center, Stanford, CA. Fax: 415-725-2395. E-mail: ml.dak@forsythe.stanford.edu. Objective: To Determine the importance of CD4 cells, quantitative HIV plasma viremia and syncytia inducing (SI) virus on 50% CD4 cell decline, AIDS, and death in a study of reverse transcriptase inhibitor (RTI) Therapy; specifically ZDV, ZDV/ ddI , ZDV/ ddC , |
| Mo.B.294 | A randomized, double-blinded comparative trial of the effects of zidovudine, didanosine and nevirapine combinations in antiviral naive, AIDS-free, HIV-infected patients with CD4 counts 200-600/mm3. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.294) Myers MW, Julios GM; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA. Fax: (203) 798-5433. Objective: To compare the safety, tolerability, immunological and virological activity of 2 and 3 drug combination therapy regimens including zidovudine (ZDV), didanosine ( ddI ) and |
| Mo.B.295 | Delavirdine (DLV) combined with zidovudine (ZDV) or didanosine (ddI) produces sustained reduction in viral burden and increases in CD4 count in early and advanced HIV-1 infection. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.295) Freimuth WW, Chuang-Stein CJ, Greenwald CA, Wathen LK, Edge-Padbury BA, Cox SR, Daenzer CL, Wang Y, Carberry PA; Pharmacia & Upjohn, Inc., Kalamazoo, MI. Objective: Delavirdine a potent non-nucleoside reverse transcriptase inhibitor, effectively inhibits both RNA- and DNA-directed polymerase functions of HIV-1 reverse transcriptase and has been shown to be synergistic with ZDV (in ZDV sensitive and resistant strains) and ddI |
| Mo.B.300 | Traditional medicine is a valid local alternative for the treatment of chronic diarrhea and Herpes zoster in AIDS patients in Kampala, Uganda. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.300) Homsy J, Kabatesi D, Kwamya L, Tusaba C, Kasolo S, Okello M, Ssentamu L, Mwebe D, Nshakira N, Mubiru F, King R, Katabira E; TASO THETA Project, Kampala, Uganda. Fax: 256-41-530'619 or 267'113 or 268'498. E-mail: msftheta@imul.com. Objective: To evaluate the effectiveness of traditional herbal medicine for the treatment of chronic diarrhea (CD) and Herpes Zoster (HZ) in HIV-infected patients in Kampala, Uganda . Methods: Trials were conducted in 2 phases. In phase I, test patients were selected, enrolled and followed-up at 3 healers clinics by t |
| Mo.B.301 | Alternative therapy use in HIV-positive women. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.301) Meneilly GP, Carr R, Brown L; Oak Tree Clinic, Vancouver, BC, Canada. Fax: 604-875-3063. E-mail:gmeneilly@unixg.ubc.ca. Objective: To characterize the use of alternative therapies in a group of HIV-positive women. Methods: Forty-two percent (26/62) of female patients attending an ambulatory HIV clinic were identified as using alternative therapies. Using a structured telephone interview, the use of alternative therapies in this populati |
| Mo.B.302 | A model of collaborative naturopathic and allopathic medicine in primary HIV health care. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.302) Luby KP, Rubin G; Rubin G The delivery of health care to patients with HIV is continually evolving, driven predominantly by our own patients as they pursue alternatives to allopathic medicine. This has necessitated openmindedness on the part of physicians and commitment to cooperation on the part of complementary therapists to ensure com |
| Mo.B.303 | Meta-survey of plant and herb material as a treatment for HIV. Int Conf AIDS 1996 Jul 7-12; 11:22 (abstract no. Mo.B.303) Chang RY, Kong XB; Cornell Medical College, New York, NY, USA. Fax: 212-717-3367. E-mail: changr@mskcc.org. Objective: To identify the current scope and nature of plant and herbal compounds and extracts potentially useful in anti-HIV treatment, and their state of research and development. Methods: A comprehensive search of the published literature since 1982 on all plant and herbal compounds or extracts screened for anti-HIV |
| Mo.B.304 | Effects of aerobic and resistive exercise on symptoms, immune status, and viral load in HIV+ men and women. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.304) Smith BA, Neidig J, Nickel J, Frid D, Para M, Fass R; The Ohio State University, Columbus, OH, USA. Fax: 614-292-4948. E-mail: Smith.73@OSU.edu. Objective: The effect of aerobic and resistive exercise on HIV+ adults has not been completely characterized. This experimental study will evaluate a supervised aerobic and resistive exercise protocol in 60 HIV+ adults with CD4 counts of 200-499. Impact on symptoms, immune markers, viral load, mood states, body composi |
| Mo.B.305 | Herbal medicine: an alternative therapy in poor rural areas. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.305) Ssemukasa M, Apio S; Concern Worldwide, Masaka, Uganda. Fax: 256-481-20514. In Rakai District, Uganda , most families with sick people due mainly to HIV/AIDS cannot afford the high cost of Western Medicine and are often reluctant to use the cheaper local herbal medicine due to uncertainty about their effectiveness. Health facilities in health centres are unavailable to the majority of the popu |
| Mo.B.310 | Disease patterns in AIDS-related focal brain lesion (FBL)-causing disorders: a prospective cohort study on neuroradiological and clinical characteristics combined with CSF PCR analysis. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.310) Ammassari A, De Luca A, Cingolani A, Fortini M, Scoppettuolo G, Murri R, Cattani P, Grillo R; Clinic Of Infection Diseases, Catholic University, Gemelli, Rome, Italy. Fax: 00396-3058512. Objective: 1. To identify disease patterns based on the combination of neuroradiological and clinical characteristics as well as PCR tests on cerebrospinal fluid (CSF) for the diagnosis of different focal brain lesion (FBL)-causing disorders in HIV+ patients (pts); 2. To build a decision-making algorithm to be employed |
| Mo.B.311 | Molecular characterization of JCV strains detected in CSF, PBMCs and urine of AIDS patients with and without PML. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.311) Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E, Losciale L, Mediati M, Vago L, Cagni A, Cereda P, Maserati R; Institute of Medical Microbiology, University of Milan, Milano, Italy. Objective: To establish the frequency and the distribution of JC virus (JCV) among AIDS patients with and without progressive multi-focal leukoencephalopathy (PML) and the relevance of different JCV strains in the pathogenesis of this demyelinating disease. Methods: JCV DNA was searched, using a nested polymerase chain |
| Mo.B.312 | A prospective, randomized trial of trimethoprim-sulphamethoxazole versus pyrimethamine-sulfadiazine in AIDS patients with cerebral toxoplasmosis. A preliminary report. Int Conf AIDS 1996 Jul 7-12; 11:23 (abstract no. Mo.B.312) Torre D, Casari S, Speranza F, Orani A, Angarano G, Chiodo G, Fiori GP, Carosi GP; Department of Infectious Diseases, Varese, Italy. Fax: 0332-265586. Objectives: The efficacy of trimethoprim-sulphamethoxazole (TMP-SMZ) in cerebral toxoplasmosis (CT) of patients with AIDS has not yet been established in randomized trial. Some retrospective studies showed that TMP-SMZ is effective in CT in AIDS patients. To determine the efficacy and tolerance of TMP-SMZ versus standa |
| Mo.B.313 | Cerebral dendritic arborization is associated with degree of cognitive impairment in HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.313) Marcotte TD, Masliah E, Heaton RK, Ellis RJ, Wiley C, Mallory M, McCutchan JA, Atkinson JH, Grant I; University of California, San Diego, CA, USA. Fax: 619-543-1235. E-mail: igrant@ucsd.edu. Objective: To determine if cortical dendritic arborization, assessed at autopsy, correlates with cognitive functioning during life in individuals who had HIV infection and varying neurocognitive impairment. Methods: Midfrontal cortical sections from 19 subjects who received a comprehensive neuropsychological (NP) and n |
| Mo.B.314 | Cerebrospinal fluid (CSF) HIV-1 RNA levels correlate with AIDS dementia complex (ADC). Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.314) Brew BJ, Pemberton L, Cunningham P, Law M; NCHECR, Sydney, Australia. Fax: 612 332 1837. E-mail: B.Brew@UNSW.edu.au. Objectives: To determine the relationships between levels of CSF HIV-1 RNA and i) the presence and severity of ADC, ii) central nervous system (CNS) infections and iii) CSF 2 microglobulin and neopterin levels. Methods: 26 patients were assessed neurologically, neuropsychologically, by CT brain scan and CSF analysis, w |
| Mo.B.315 | Evidence for biochemical changes in the frontal lobe of HIV-infected individuals without ADC. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.315) Lenkinski RE, Lopez-Villegas D, Frank I; Hospital of the Univ. of Pennsylvania, Philadelphia, PA. Objective: There has been recent interest in employing proton Magnetic Resonance Spectroscopy (MRS) to study the effects of HIV infection in the CNS. Since it has been shown that neuronal damage occurs in the intermediate or late stages of disease our goal was to determine whether MRS could detect metabolic alterations |
| Mo.B.410 | Saquinavir (invirase, SQV) vs. HIVID (zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (zidovudine, ZDV). Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.410) Salgo MP, Beattie D, Bragman K, Donatacci L, Jones M, Montgomery L; Hoffmann-La Roche, Nutley, NJ. Fax: (201) 812-3629. Objective: The objective of this randomized, double-blind, phase II/III, multicenter study was to compare the safety, tolerability and efficacy of SQV and ddC , alone and in combination, based on clinical endpoints and laboratory markers of immunological and virologic activity. Methods: A total of 978 HIV-infected pati |
| Mo.B.411 | Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update. Int Conf AIDS 1996 Jul 7-12; 11:24 (abstract no. Mo.B.411) Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D; Ottawa General Hospital, Ottawa, Ontario, Canada. Fax: 613-737-8682. E-mail: bcameron@aixl.uottawa.ca. Objective: Ritonavir is a potent, orally bioavailable HIV protease inhibitor. We designed and conducted an international multi-centre randomized placebo-controlled clinical trial of ritonavir 600 mg twice daily for outcomes of death and new AIDS-defining illnesses or selected recurrences (pneumocystis pneumonia, esopha |
| Mo.B.412 | Extended follow-up of patients in a study of indinavir at 800 mg q8h (2.4 g/d), 1000 mg q8h (3.0 g/d) and 800 mg q6h (3.2 g/d). Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.412) Steigbigel R, Berry P, Teppler H, Mellors J, Drusano G, Leavitt R, Hildebrand C, Jonas L, Nessly M, Deutsch P, Chodakewitz J; State Univ. of New York at Stony Brook, Stony Brook, NY. Fax: 516-444-7518. Objectives: To obtain long-term (48 weeks) information on the antiviral effect of indinavir (IDV) at greater than or equal 2.4 g/d. Methods: IDV studies have demonstrated that initiation of therapy with 2.4 g/d results in greater and more sustained changes in CD4 counts and viral RNA than lower doses over 24 weeks. |
| Mo.B.413 | A randomized phase II study of VIRACEPT, a novel HIV protease inhibitor, used in combination with stavudine (d4T) vs. stavudine (d4T) alone. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.413) Gathe J Jr, Burkhardt B, Hawley P, Conant M, Peterkin J, Chapman S; Houston Clinical Research Network, Houston, TX, USA. Fax: (713) 528-4923. Objective: To evaluate the safety and efficacy of the combination of VIRACEPT and d4T versus d4T alone. Methods: A total of 33 HIV-positive have been enrolled in a ongoing pilot clinical study of the safety and efficacy of the combination of VIRACEPT and d4T versus d4T alone. Patients are d4T-naive with CD4 cell counts |
| Mo.B.414 | Causes of long term efficacy and/or drug failure in protease (PR) inhibitor monotherapy. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.414) Schapiro JM, Winters MA, Vierra M, Vanhove G, Jacobsen H, Gingeras TR, Crawford SD, Mous J, Blaschke TF, Merigan TC; Stanford University School of Medicine, Stanford, CA. Fax: 415-725-2395. E-mail: JMS.Leland.Stanford.edu. We conducted a clinical trial in 40 HIV+ volunteers who received 3600 or 7200 mg/day saquinavir monotherapy for 24-88 weeks depending on virological and immunological response. Although almost all patients showed a significant rise in CD4 counts and drop in viral load, the duration of this response varied widely throug |
| Mo.B.415 | Safety and efficacy of ritonavir administered at two potentially maximum tolerated doses. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.415) Hicks CB, Lehman L, Eron, Horton J, Jemsek J, Kelly N, Leonard J; Duke University Medical Center, Durham, NC, USA. Fax: 919-681-8474. E-mail: cbhicks@acpub.duke.edu. Objective: To evaluate the antiviral activity/safety of ritonavir in an open-label study of potentially maximum tolerated doses in HIV-infected patients with greater than or equal50 CD4 cells/mm3. Methods: Multicenter, open-label study of 30 HIV-infected patients with CD4 cell counts greater than or equal 50 CD4/mm3, v |
| Mo.B.420 | Hormonal and chronobiological impairment of GH-IGFI-IGFBP3 axis in HIV-infected patients (CDC C3) with wasting syndrome. Effects of treatment with recombinant human GH. Int Conf AIDS 1996 Jul 7-12; 11:25 (abstract no. Mo.B.420) Solerte SB, Fioravanti M, Rondanelli M, Vignati G, Scevola D, Locatelli M, Ferrari E, Minoli R; Dept. Internal Medicine, Pavia (Italy). Fax: 0039.382.24270. Objective: It is still unclear the significance of endocrine alterations often described in AIDS patients. The controversy concerns the possible relevance of these changes in the clinical progression of the disease or the evaluation of endocrine dysfunctions as a consequence of HIV infection. On this light we studied t |
| Mo.B.421 | Different body composition changes in men and women with AIDS. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.421) Kotler DP, Engelson ES, Thea DM, Wang J, Pierson RN, Saint-Louis M, Keusch GT; St. Luke's/Roosevelt Hosp. Ctr., New York, NY. Fax: (212) 523-3678. Objective: To compare the effects of gender, race, environment, and disease (AIDS) upon body composition and upon the relative depletion of body cell mass (BCM), fat free mass (FFM) and body fat. Methods: We analyzed the results of body composition studies performed in two cohorts of subjects, totalling 1415 people, in |
| Mo.B.422 | A phase III study of recombinant human growth hormone (mammalian cell-derived) in patients with AIDS wasting. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.422) Berger DS, LaMarca A, Landy H, Kauffman RS, Breitmeyer J; Center for Special Immunology, Chicago, IL, USA. Fax: 312-296-1097. Decreased body cell mass/lean body mass is an independent prognostic factor in AIDS for early mortality and morbidity. A previous Phase III clinical trial of mammalian cell-derived recombinant human growth hormone (r-hGH[m], Serostim , Serono Laboratories, Inc., Norwell MA) resulted in significant weight (wgt) gain, an |
| Mo.B.423 | A prospective study on the safety and effect of nandrolone decanoate in HIV-positive patients. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.423) Bucher G, Berger DS, Fields-Gardner C, Jones R, Reiter WM; Center for Special Immunology, Chicago, IL, USA. Fax: 312-296-1097. Objectives:There have been anecdotal reports of wide anabolic steroid use in HIV-positive patients for hypogonadism, fatigue, depression, and/or wasting. We report the first controlled trial on the safety of nandrolone decanoate (Nd) (Deca-Durabolin, Organon) in HIV-positive individuals. Methods: In a 12-week randomize |
| Mo.B.424 | Fat malabsorption assessed by 14C-triolein breath test in HIV-positive patients in different stages of infection: is it an early event? Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.424) Machado FR, Coelho LGV, Chausson Y, Greco DB; Infectious and Parasitic Diseases Service, Belo Horizonte, MG, Brasil. Fax: 55-31-224-8801. Objective: Evaluation of fat absorption in HIV+ patients, in different phases of HIV infection. Methods: Between November 1994 and February 1995, 47 consecutive HIV+ individuals on follow up at the Immunodeficiency Clinic, after informed consent, underwent a 14C-triolein breath test for evaluation of fat absorption. Te |
| Mo.B.425 | Infectious HIV viral load, body mass index and weight change in IDUs and gay men. Int Conf AIDS 1996 Jul 7-12; 11:26 (abstract no. Mo.B.425) Levy DA, Graham N, Munoz A, Saah AJ, Vlahov D, Farzadegam H; Johns Hopkins SHPH, Baltimore, MD, USA. Fax: 410-955-1836. Objective: To examine the relationship between infectious viral load, and body mass index (BMI) and weight change, and to determine if the relationship is modified by other factors known to be associated with weight loss. Methods: Infectious HIV viral load was measured by quantitative microculture on 511 participants i |
| Mo.B.430 | Antiherpes virus treatment and risk of Kaposi's sarcoma in HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. Mo.B.430) Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN; HIV Research Unit, Dept Primary Care and Population Sciences, Royal Free Hospital School of Medicine, London, UK. Fax: 01717941224. Introduction and Objective: With the recent identification of a new herpes virus in patients with Kaposi s sarcoma, there have been several reports on the use of antiherpes therapy (foscarnet, ganciclovir and acyclovir ) and risk of developing Kaposi s sarcoma. We therefore investigated the association between use of a |
| Mo.B.431 | AIDS-associated lymphoma is preceded by the over-expression of molecules associated with B cell activation and immunoglobulin (Ig) isotype switching. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. Mo.B.431) Martinez-Maza O, van der Meijden M, Widney D, Yawetz S; Department of Microbiology & Immunology, UCLA School of Medicine, Los Angeles, CA, USA. Fax: (310) 206-5387. E-mail: omartine@microimmun.medsch.ucla.edu. Objective: To determine if elevated levels of molecules associated with B cell hyperactivation or Ig isotype switching preceded the development of AIDS- lymphoma , we measured serum levels of various immune system factors associated with these processes, including serum sCD23 (a B cell differentiation/activation factor |
| Mo.B.432 | Phase I-II clinical trial supports safety and efficacy of ALRT 1057 topical retinoid gel for Kaposi's sarcoma. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. Mo.B.432) Duvic M, Friedman-Kien AE, Galpin J, Miles SA, Looney DJ, Myskowski PL, Gill G, Truglia J, Yocum R; Department of Dermatology, Houston, TX. Objective: To assess the safety and effectiveness of a new topical retinoid, ALRT 1057 (9-cis-retinoic acid) for the treatment of Kaposi s sarcoma. Methods: Sixty-three patients with biopsy-proven, multiple KS lesions enrolled in a controlled Phase I-II study at 6 centers. Patients applied 0.05% or 0.1% gel to selected |
| Mo.B.433 | Burkitt's lymphoma (BL) in 75 patients (pts), 46 with and 29 without HIV infection: a monoinstitutional study. Int Conf AIDS 1996 Jul 7-12; 11:27 (abstract no. Mo.B.433) Santarossa S, Spina M, Zagonel V, Carbone A, Talamini R, Abbruzzese L, Errante D, Monfardini S, Tirelli U; Division of Medical Oncology and AIDS, Centro di Riferimento Oncologico, Aviano, Italy. Fax: 434/659531. Objective: To compare the clinical features and outcome of pts with BL in HIV setting and in the general population. Methods: We retrospectively analysed 75 pts (46 with and 29 without HIV infection) diagnosed and treated at Aviano Cancer Center, Italy , from May 1987 to June 1995. Results: Pts with BL and HIV infectio |
| Mo.B.434 | Risk factors in mothers of children with Kaposi's sarcoma (KS): a case control study. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.434) Mwidu S, Ziegler JL, Katongole-Mbidde E, Tindyebwa D, Marum L, Newton R, Beral V, Parkin DM, DeCock KM, Jaffe H, Weiss R; The Centre, Harare, Zimbabwe. Fax: 263-4-724384. Objective: To determine the risk factors for childhood KS and to assess whether KSHV (HHV-8), the putative aetiological agent of KS, is transmissible from mother to child. Methods: Since January, 1995, newly diagnosed children with KS (cases) have been registered and their mothers interviewed. For every case 3 children |
| Mo.B.435 | Curative therapy for AIDS cancers. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.435) Miles SA; UCLA Care Center, Los Angeles, CA, USA. Fax: 310-206-3311. Many AIDS clinicians view patients with AIDS-related malignancies as uncurable. Recent laboratory and clinical data suggest that successful treatment may already be here for may of these patients. For example, the recent identification of the Kaposi s sarcoma herpes virus (HHV-8) and partial genomic cloning have provid |
| Mo.B.531 | A rational approach to the use of antiretroviral agents. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.531) Vella S, Floridia M; Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy. Fax: 39-6-4457-582. E-mail: vella@virus1.iss.infn.it. The number of antiretroviral drugs available for treatment is currently high enough to allow a considerable variety of strategies (e.g. early versus late), of combinations and of sequential regimens, which can also be better tailored to the medical status and preferences of the individual patient. In the design of firs |
| Mo.B.533 | Formulating rational use of anti-retrovirals in Thailand. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.533) Prescott N, Kunanusont C, Phoolcharoen W, Rojanapitayakorn W, Perriens J, Boonyuen D; AIDS Division, Dept of CDC, Ministry of Public Health, Thailand. E-mail:chaiyos@health.moph.go.th. Background: An evaluation of antiretroviral policy options was conducted in 1995- 3 years after initiation of government-subsidised Zidovudine (ZDV) in Thailand . Experts from the World Bank, the World Health Organization , Thai universities, and the Thai Ministry of Public Health formed joint working groups on epidemi |
| Mo.B.540 | Menstrual abnormalities in women with HIV infection. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.540) Cohen MH, Greenblatt R, Minkoff H, Barkan S, Burns D, Denenberg R, Young M, Levine A; Chicago, IL, USA. Fax: (312) 633-4902. E-mail: mcohen@hektoen.org. Objective: To determine the prevalence and etiology of amenorrhea and to describe menstrual abnormalities in women with HIV infection. Methods: The Women s Interagency HIV Study (WIHS) is a multi-site cohort study of HIV-infected women and a comparable at risk uninfected control group. Data for this analysis was availa |
| Mo.B.541 | Reduced fertility among HIV-infected women. Results of cross-sectional and prospective studies in rural Uganda. Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. Mo.B.541) Gray RH, Wawer MJ, Wabwire-Mangen F, Sewenkambo N, Serwadda D, Kigonzi G, Paxton L, Li C, Yan Y, McNairn D, Kiwanuka N; Department of Population Dynamics, Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, USA. Fax: (410) 955-0792. E-mail: gray@hpcsun01.sph.jhu.edu. Johns Hopkins University, Baltimore, USA, Columbia University, New York, Makerere University, Kampala, Uganda . Objectives: To assess the association between HIV infection, STDs and fertility in two studies from rural Uganda. Methods: Data were derived from two studies in Rakai District, southwestern Uganda. These were |
| Mo.B.542 | Incidence of pregnancy in a European cohort of HIV-infected women. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. Mo.B.542) De Vincenzi I; European Centre for the Epidemiological Monitoring of AIDS, St-Maurice, France. Fax: 33 1 43 96 50 81. E-mail: idvceses@b3e.jussieu.fr. Objective: To analyse the impact of HIV testing on the incidence of pregnancy among HIV-infected women. Methods: The analysis is based on data collected at inclusion in a multicentre European cohort of HIV(+) women with a known date of infection. The incidence of pregnancies conceived in the year preceding the first HI |
| Mo.B.543 | Pregnant HIV-infected women in Europe. Int Conf AIDS 1996 Jul 7-12; 11:29 (abstract no. Mo.B.543) Newell ML; Epidemiology Unit, Institute of Child Health, London, UK. Fax: 0171 813 8233. E-mail: M.Newell@ich.bpmf.ac.uk. |